Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 8/2015

01-08-2015 | Neurology of Systemic Diseases (J Biller, Section Editor)

Neurologic Complications of Chronic Kidney Disease

Authors: Kavitha Vellanki, Vinod K. Bansal

Published in: Current Neurology and Neuroscience Reports | Issue 8/2015

Login to get access

Abstract

Chronic kidney disease (CKD) is an increasing problem worldwide and is now being recognized as a global health burden particularly for cardiovascular and cerebrovascular events. The incidence of stroke increases in the presence of CKD with a 3-fold increased rate reported in ESRD. Atrial fibrillation (AF) increases the risk of stroke in CKD. There is conflicting observational evidence regarding benefit of anticoagulation in CKD for prevention of stroke in AF as risk of bleeding is high. Overall, anticoagulant in CKD may be beneficial in appropriate patients with meticulous monitoring of international normalized ratio (INR). Neurological manifestations related to electrolyte disorders, drug toxicity, and uremia are common in CKD. Appropriate drug dosing, awareness of potential side effects of medications, prompt diagnosis, and treatment are essential in preventing long-term morbidity and mortality.
Literature
1.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2013;3:1–150.CrossRef
2.
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimensions and perspectives. Lancet. 2013;382:260–72.PubMedCrossRef
3.•
Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13:823–33. Review article discussing the cerebro-renal axis of neurological disorders.PubMedCrossRef
4.
5.
6.
Ovbiagele B, Wing JJ, Menon RS, et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke. 2013;44:2409–13.PubMedCrossRef
7.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610–5.PubMedCrossRef
8.
Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013;24:353–63.PubMedCrossRef
9.
10.
Wang HH, Hung SY, Sung JM, Hung KY, Wang JD. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis. 2014;63:604–11.PubMedCrossRef
11.
Muntner P, Judd SE, McClellan W, et al. Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Nephrol Dial Transplant. 2012;27:166–73.PubMedCentralPubMedCrossRef
12.••
Masson P, Webster AC, Hong M, Turner R, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol. Dial. Transplant. First published online February 12, 2015. Meta-analysis and systematic review of studies assessing the risk of stroke in CKD. A total of 83 studies; 63 cohort (N = 2085225) and 20 randomized (N = 168516) trails reporting 30,392 strokes in total were assessed. A thorough review of all published data so far.
13.
Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular and all-cause mortality: a pooled analysis of community based studies. JASN. 2004;15:1307–15.PubMedCrossRef
14.
Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159:1102–7.PubMedCentralPubMedCrossRef
15.•
Genovesi S, Rossi E, Gallieni M, Stella A, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015;30(3):491–8. Prospective observational study assessing mortality and bleeding risk in dialysis patients with atrial fibrillation receiving warfarin for anti-coagulation.PubMedCrossRef
16.••
Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35. Retrospective cohort review of Danish national registries of all patients discharged from the hospital with diagnosis of atrial fibrillation. Warfarin decreased the risk of stroke in patients with non-end stage renal disease and also in patients who received renal replacement therapy.PubMedCrossRef
17.•
Bondi AN, Lip GYH, Kamper AL, Hansen PR, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. JACC. 2014;64:2472–82. Retrospective cohort study assessing the risk of stroke in CKD by individual in CHA2DS2-VASc score and benefit of warfarin in each individual group.
18.
Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? JAMA. 2014;311:913–5.PubMedCrossRef
19.
Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–33.PubMedCentralPubMedCrossRef
20.•
Shah M, Tsadok AM, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196–203. Population based retrospective study of dialysis patients with atrial fibrillation receiving warfarin involving Canadian population. Similar to Chan et al. from 2009, warfarin use did not show any benefit in stroke risk reduction but risk of bleeding was as high as 44%.PubMedCrossRef
21.
Howard G, Cushman M, Howard VJ, Kissela BM, et al. Risk factors for intracerebral hemorrhage. The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke. 2013;44:1282–7.PubMedCentralPubMedCrossRef
22.
El Husseini, Nada, et al. Chronic Kidney Disease and Stroke. Adv Chronic Kidney Dis, 21;(6):500–508
23.•
Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke. 2013;44:2935–41.PubMedCrossRef
24.
Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens. 2010;28:1738–44.PubMedCrossRef
25.
Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:2946–53.PubMedCentralPubMedCrossRef
26.
Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc. 2012;1, e002097.PubMedCentralPubMedCrossRef
27.
Nakagawa K, Hirai T, Takashima S, et al. Chronic kidney disease and CHADS (2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011;107:912–6.PubMedCrossRef
28.
Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts. Circulation. 2013;127:224–32.PubMedCrossRef
29.
Bautista J, Bellac A, Chaudhari A, Pekler G, et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J. 2015;0:1–6.
30.
Reinecke H, Brand E, Mesters R, Schabitz WR, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. JASN. 2009;20(4):705–11.PubMedCrossRef
31.
US Renal Data System. USRDS. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
32.
Sozio SM, Armstrong PA, Coresh J, Jaar BG, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. AJKD. 2009;54(3):468–77.PubMedCentralPubMedCrossRef
33.
Krishna PR, Naresh S, Krishna GSR, Lakshmi AY, et al. Stroke in chronic kidney disease. Ind J Nephrol. 2009;19(1):5–7.CrossRef
34.
Lee JG, Lee KB, Jang IM, et al. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc Dis. 2013;35:53–9.PubMedCrossRef
35.
Molshatzki N, Orion D, Tsabari R, et al. Chronic kidney disease in patients with acute intracerebral hemorrhage: association with large hematoma volume and poor outcome. Cerebrovasc Dis. 2011;31:271–7.PubMedCrossRef
36.
Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. J Neurol Sci. 2011;301:46–50.PubMedCrossRef
37.
Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study. Am J Kidney Dis. 2012;59:249–57.PubMedCrossRef
38.
Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke. 2009;40:1296–303.PubMedCrossRef
39.
Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293–9.PubMedCrossRef
40.
Lyrer PA, Fluri F, Gisler D, Papa S, et al. Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology. 2008;71:1548–50.PubMedCrossRef
41.
Naganuma M, Koga M, Shiokawa Y, et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis. 2011;31:123–9.PubMedCrossRef
42.
Gensicke H, Zinkstok AM, Roos YB, et al. IV thrombolysis and renal function. Neurology. 2013;81:1780–8.PubMedCrossRef
43.••
Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311:919–28. Prospective observational multi-center cohort study from Swedish web based registry assessing 1 yr. mortality in patients with compromised renal function and atrial fibrillation who were receiving warfarin. Outcomes were pre-defined and all participants had a confirmed diagnosis of atrial fibrillation.PubMedCrossRef
44.
Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.PubMedCrossRef
45.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64(21):e1–76.PubMedCrossRef
46.
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.PubMedCrossRef
47.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRef
48.
Sarnak MJ, Tighiouart H, Scott TM, et al. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013;80:471–80.PubMedCentralPubMedCrossRef
49.
Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. Neurology. 2006;67:216–23.PubMedCrossRef
50.
Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc. 2004;52:1863–9.PubMedCrossRef
51.
52.
Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol. 2012;35(5):474–82.PubMedCrossRef
53.
Kovesdy C, Lott E, Lu J, Malakauskas S, et al. Hyponatremia, hypernatremia and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125(5):677–84.PubMedCentralPubMedCrossRef
54.•
Sterns RH. Disorders of plasma sodium—causes, consequences, and correction. N Engl J Med. 2015;372:55–65. Review article exploring the etiology of sodium disorders and discussing the pathophysiology of neurological manifestations of overzealous correction.PubMedCrossRef
55.
Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–7.PubMedCrossRef
56.
Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalemia. Br J Anaesth. 1993;70(2):226–7.PubMedCrossRef
57.
Siegel D, Hulley SB, Black DM, Cheitlin MD, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267(8):1083.PubMedCrossRef
58.
Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol. 2010;25:2413–30.PubMedCrossRef
59.
Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. CJASN. 2009;4(1):221–33.PubMed
60.
Jha V. Commonly used renal drugs. In: Biller J, editor. Interface of neurology and internal medicine. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 211–6.
61.
Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107(1):1–16.PubMedCrossRef
62.
Heidland A, Sebekova K, Klassen A, Palkovits M. Mechanisms of acute uremic encephalopathy: early activation of Fos and Fra-2 gene products in different nuclei/areas of the rat brain. J Ren Nutr. 2010;20(5 Suppl):S44–50.PubMedCrossRef
63.
Metadata
Title
Neurologic Complications of Chronic Kidney Disease
Authors
Kavitha Vellanki
Vinod K. Bansal
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 8/2015
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-015-0577-6

Other articles of this Issue 8/2015

Current Neurology and Neuroscience Reports 8/2015 Go to the issue

Behavior (HS Kirshner, Section Editor)

Update in Aphasia Research

Dementia (KS Marder, Section Editor)

TMS as a Tool for Examining Cognitive Processing

Neuroimaging (DJ Brooks, Section Editor)

How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?

Neuroimaging (DJ Brooks, Section Editor)

Does Stroke Imaging Provide Insights into the Neural Basis of Cognition?

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis

Behavior (HS Kirshner, Section Editor)

The Inflammatory Form of Cerebral Amyloid Angiopathy or “Cerebral Amyloid Angiopathy-Related Inflammation” (CAARI)